Current Status of COVID-19 Therapies and Drug Repositioning Applications
Ozlem Altay,
Elyas Mohammadi,
Simon Lam,
Hasan Turkez,
Jan Boren,
Jens Nielsen,
Mathias Uhlen,
Adil Mardinoglu
Affiliations
Ozlem Altay
Science for Life Laboratory, KTH – Royal Institute of Technology, Stockholm 17121, Sweden
Elyas Mohammadi
Science for Life Laboratory, KTH – Royal Institute of Technology, Stockholm 17121, Sweden; Department of Animal Science, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran
Simon Lam
Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London SE1 9RT, UK
Hasan Turkez
Department of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum 25240, Turkey
Jan Boren
Department of Molecular and Clinical Medicine, University of Gothenburg, The Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg 41345, Sweden
Jens Nielsen
Department of Biology and Biological Engineering, Chalmers University of Technology, SE-Gothenburg, 41296, Sweden
Mathias Uhlen
Science for Life Laboratory, KTH – Royal Institute of Technology, Stockholm 17121, Sweden
Adil Mardinoglu
Science for Life Laboratory, KTH – Royal Institute of Technology, Stockholm 17121, Sweden; Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London SE1 9RT, UK; Corresponding author
The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. Here, we review current information concerning the global health issue of COVID-19 including promising approved drugs and ongoing clinical trials for prospective treatment options. In addition, we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against SARS-CoV-2.
